Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 18/2017

01-12-2017 | Systematic Review

Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years

Authors: G. Voegeli, M. L. Cléry-Melin, N. Ramoz, P. Gorwood

Published in: Drugs | Issue 18/2017

Login to get access

Abstract

Background

Antidepressant drugs are widely prescribed, but response rates after 3 months are only around one-third, explaining the importance of the search of objectively measurable markers predicting positive treatment response. These markers are being developed in different fields, with different techniques, sample sizes, costs, and efficiency. It is therefore difficult to know which ones are the most promising.

Objective

Our purpose was to compute comparable (i.e., standardized) effect sizes, at study level but also at marker level, in order to conclude on the efficacy of each technique used and all analyzed markers.

Methods

We conducted a systematic search on the PubMed database to gather all articles published since 2000 using objectively measurable markers to predict antidepressant response from five domains, namely cognition, electrophysiology, imaging, genetics, and transcriptomics/proteomics/epigenetics. A manual screening of the abstracts and the reference lists of these articles completed the search process.

Results

Executive functioning, theta activity in the rostral Anterior Cingular Cortex (rACC), and polysomnographic sleep measures could be considered as belonging to the best objectively measured markers, with a combined d around 1 and at least four positive studies. For inter-category comparisons, the approaches that showed the highest effect sizes are, in descending order, imaging (combined d between 0.703 and 1.353), electrophysiology (0.294–1.138), cognition (0.929–1.022), proteins/nucleotides (0.520–1.18), and genetics (0.021–0.515).

Conclusion

Markers of antidepressant treatment outcome are numerous, but with a discrepant level of accuracy. Many biomarkers and cognitions have sufficient predictive value (d ≥ 1) to be potentially useful for clinicians to predict outcome and personalize antidepressant treatment.
Literature
1.
Kessler RC, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization’s World Mental Health Survey Initiative. World Psychiatry Off J World Psychiatr Assoc WPA. 2007;6(3):168–76.
2.
Thase ME, et al. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry J Ment Sci. 2001;178:234–41.CrossRef
3.
Ciudad A, et al. Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study. J Clin Psychiatry. 2012;73(2):185–91.PubMedCrossRef
4.
Gorwood P, et al. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry. 2008;165(6):731–9.PubMedCrossRef
5.
Stauffer VL, et al. Is the noradrenergic symptom cluster a valid construct in adjunctive treatment of major depressive disorder? J Clin Psychiatry. 2017;78(3):317–23.PubMedCrossRef
6.
Austin MP, et al. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry J Ment Sci. 2001;178:200–6.CrossRef
7.
Paelecke-Habermann Y, et al. Attention and executive functions in remitted major depression patients. J Affect Disord. 2005;89(1–3):125–35.PubMedCrossRef
8.
Jaeger J, Berns S, et al. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145(1):39–48.PubMedCrossRef
9.
Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160(4):636–45.PubMedCrossRef
10.
Den Hartog HM, et al. Cognitive functioning in young and middle-aged unmedicated out-patients with major depression: testing the effort and cognitive speed hypotheses. Psychol Med. 2003;33(8):1443–51.CrossRef
11.
12.
Clark L, et al. Neurocognitive mechanisms in depression: implications for treatment. Annu Rev Neurosci. 2009;32:57–74.PubMedCrossRef
13.
Hasler G, et al. Discovering endophenotypes for major depression. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2004;29(10):1765–81.CrossRef
14.
15.
Mössner R, et al. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2007;8(3):141–74.CrossRef
16.
17.
Crane NA, et al. Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain J Neurol. 2017;140(Pt 2):472–86.CrossRef
18.
Baskaran A, et al. The neurobiology of the EEG biomarker as a predictor of treatment response in depression. Neuropharmacology. 2012;63(4):507–13.PubMedCrossRef
19.
Franchini L, et al. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res. 1998;32(5):255–9.PubMedCrossRef
20.
Gorlyn M, et al. Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm Vienna Austria 1996. 2008;115(8):1213–9.
21.
22.
Antypa N, et al. The neuropsychological hypothesis of antidepressant drug action revisited. CNS Neurol Disord Drug Targets. 2014;13(10):1722–39.PubMedCrossRef
23.
24.
Pizzagalli D, et al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry. 2001;158(3):405–15.PubMedCrossRef
25.
Gyurak A, et al. Frontoparietal activation during response inhibition predicts remission to antidepressants in patients with major depression. Biol Psychiatry. 2016;79(4):274–81.PubMedCrossRef
26.
Gorwood P, et al. Psychomotor retardation is a scar of past depressive episodes, revealed by simple cognitive tests. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2014;24(10):1630–40.CrossRef
27.
Kessing LV. Cognitive impairment in the euthymic phase of affective disorder. Psychol Med. 1998;28(5):1027–38.PubMedCrossRef
28.
Boeker H, et al. Sustained cognitive impairments after clinical recovery of severe depression. J Nerv Ment Dis. 2012;200(9):773–6.PubMedCrossRef
29.
Weiland-Fiedler P, et al. Evidence for continuing neuropsychological impairments in depression. J Affect Disord. 2004;82(2):253–8.PubMedCrossRef
30.
Cléry-Melin M-L, Gorwood P. A simple attention test in the acute phase of a major depressive episode is predictive of later functional remission. Depress Anxiety. 2017;34(2):159–70.PubMedCrossRef
31.
Taylor BP, et al. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry. 2006;163(1):73–8.PubMedCrossRef
32.
Herrera-Guzmán I, et al. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Res. 2008;160(1):72–82.PubMedCrossRef
33.
Vrieze E, et al. Reduced reward learning predicts outcome in major depressive disorder. Biol Psychiatry. 2013;73(7):639–45.PubMedCrossRef
34.
Vrieze E, et al. Dimensions in major depressive disorder and their relevance for treatment outcome. J Affect Disord. 2014;155:35–41.PubMedCrossRef
35.
Spronk D, et al. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study. J Affect Disord. 2011;128(1–2):41–8.PubMedCrossRef
36.
Dunkin JJ, et al. Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord. 2000;60(1):13–23.PubMedCrossRef
37.
Majer M, et al. Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders. Psychol Med. 2004;34(8):1453–63.PubMedCrossRef
38.
Langenecker SA, et al. Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder. Biol Psychiatry. 2007;62(11):1272–80.PubMedPubMedCentralCrossRef
39.
Tadić A, et al. Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with major depressive disorder. BMC Psychiatry. 2011;11:16.PubMedPubMedCentralCrossRef
40.
Trivedi MH, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design. J Psychiatr Res. 2016;78:11–23.PubMedCrossRefPubMedCentral
41.
42.
43.
Bares M, et al. The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2010;20(7):459–66.CrossRef
44.
Linka T, et al. The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression. Pharmacopsychiatry. 2005;38(3):139–43.PubMedCrossRef
45.
Linka T, et al. The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression. Neurosci Lett. 2004;367(3):375–8.PubMedCrossRef
46.
Gallinat J, et al. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berlin. 2000;148(4):404–11.CrossRef
47.
Lee T-W, et al. Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression. J Psychiatry Neurosci JPN. 2005;30(3):202–5.PubMed
48.
Juckel G, et al. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. J Clin Psychiatry. 2007;68(8):1206–12.PubMedCrossRef
49.
Murck H, et al. State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2003;28(2):348–58.CrossRef
50.
Leuchter AF, et al. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res. 2009;169(2):132–8.PubMedCrossRef
51.
Cook IA, et al. Midline and right frontal brain function as a physiologic biomarker of remission in major depression. Psychiatry Res. 2009;174(2):152–7.PubMedPubMedCentralCrossRef
52.
Bruder GE, et al. Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings. Biol Psychiatry. 2008;63(12):1171–7.PubMedCrossRef
53.
Bruder GE, et al. Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry. 2001;49(5):416–25.PubMedCrossRef
54.
Cook IA, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2002;27(1):120–31.CrossRef
55.
Bares M, et al. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Eur Psychiatry J Assoc Eur Psychiatr. 2008;23(5):350–5.CrossRef
56.
van Dinteren R, et al. Utility of event-related potentials in predicting antidepressant treatment response: an iSPOT-D report. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2015;25(11):1981–90.CrossRef
57.
Duncan WC, et al. Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. J Affect Disord. 2013;145(1):115–9.PubMedCrossRef
58.
Adamczyk M, et al. Cordance derived from REM sleep EEG as a biomarker for treatment response in depression—a naturalistic study after antidepressant medication. J Psychiatr Res. 2015;63:97–104.PubMedCrossRef
59.
Olbrich S, et al. CNS- and ANS-arousal predict response to antidepressant medication: findings from the randomized iSPOT-D study. J Psychiatr Res. 2016;73:108–15.PubMedCrossRef
60.
Lee T-W, et al. The implication of functional connectivity strength in predicting treatment response of major depressive disorder: a resting EEG study. Psychiatry Res. 2011;194(3):372–7.PubMedCrossRef
61.
Caudill MM, et al. The antidepressant treatment response index as a predictor of reboxetine treatment outcome in major depressive disorder. Clin EEG Neurosci. 2015;46(4):277–84.PubMedCrossRef
62.
Cook IA, et al. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial. J Clin Psychiatry. 2013;74(1):51–6.PubMedCrossRef
63.
Hunter AM, et al. The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine. J Clin Neurophysiol Off Publ Am Electroencephalogr Soc. 2011;28(5):478–82.
64.
Hunter AM, et al. Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. J Psychiatr Res. 2010;44(2):90–8.PubMedCrossRef
65.
Iosifescu DV, et al. Frontal EEG predictors of treatment outcome in major depressive disorder. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2009;19(11):772–7.CrossRef
66.
Tenke CE, et al. Current source density measures of electroencephalographic alpha predict antidepressant treatment response. Biol Psychiatry. 2011;70(4):388–94.PubMedPubMedCentralCrossRef
67.
Bares M, et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. J Psychiatr Res. 2007;41(3–4):319–25.PubMedCrossRef
68.
Bares M, et al. The effectiveness of prefrontal theta cordance and early reduction of depressive symptoms in the prediction of antidepressant treatment outcome in patients with resistant depression: analysis of naturalistic data. Eur Arch Psychiatry Clin Neurosci. 2015;265(1):73–82.PubMedCrossRef
69.
Knott V, et al. Pre-treatment EEG and it’s relationship to depression severity and paroxetine treatment outcome. Pharmacopsychiatry. 2000;33(6):201–5.PubMedCrossRef
70.
Mulert C, et al. Rostral anterior cingulate cortex activity in the theta band predicts response to antidepressive medication. Clin EEG Neurosci. 2007;38(2):78–81.PubMedCrossRef
71.
Korb AS, et al. Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression. Clin Neurophysiol Off J Int Fed Clin Neurophysiol. 2009;120(7):1313–9.CrossRef
72.
Leuchter AF, et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study. Psychiatry Res. 2009;169(2):124–31.PubMedCrossRef
73.
Cook IA, et al. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J Psychiatr Res. 2005;39(5):461–6.PubMedCrossRef
74.
Hunter AM, et al. Rostral anterior cingulate activity in major depressive disorder: state or trait marker of responsiveness to medication? J Neuropsychiatry Clin Neurosci. 2013;25(2):126–33.PubMedCrossRef
75.
Rush AJ, Giles DE, Jarrett RB, Feldman-Koffler F, Debus JR, Weissenburger J, Orsulak PJ, Roffwarg HP. Reduced REM latency predicts response to tricyclic medication in depressed outpatients. Biol Psychiatry. 1989;26(1):61–72.PubMedCrossRef
76.
Kalayam B, Alexopoulos GS. Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry. 1999;56(8):713–8.PubMedCrossRef
77.
Luthringer R, Minot R, Toussaint M, Calvi-Gries F, Schaltenbrand N, Macher JP. All-night EEG spectral analysis as a tool for the prediction of clinical response to antidepressant treatment. Biol Psychiatry. 1995;38(2):98–104.PubMedCrossRef
78.
Gillin JC, Wyatt RJ, Fram D, Snyder F. The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline. Psychopharmacology (Berl). 1978;59(3):267–72.PubMedCrossRef
79.
Fu CHY, et al. Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis. 2013;52:75–83.PubMedCrossRef
80.
81.
Li C-T, et al. Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study. NeuroImage. 2010;50(1):347–56.PubMedCrossRef
82.
Gong Q, et al. Prognostic prediction of therapeutic response in depression using high-field MR imaging. NeuroImage. 2011;55(4):1497–503.PubMedCrossRef
83.
Liu F, et al. Classification of different therapeutic responses of major depressive disorder with multivariate pattern analysis method based on structural MR scans. PLoS One. 2012;7(7):e40968.PubMedPubMedCentralCrossRef
84.
Chen C-H, et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry. 2007;62(5):407–14.PubMedCrossRef
85.
Williams LM, et al. Amygdala reactivity to emotional faces in the prediction of general and medication-specific responses to antidepressant treatment in the randomized iSPOT-D trial. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2015;40(10):2398–408.CrossRef
86.
Saxena S, et al. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry. 2003;160(3):522–32.PubMedCrossRef
87.
Little JT, et al. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry. 2005;57(3):220–8.PubMedCrossRef
88.
Rizvi SJ, et al. Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. J Affect Disord. 2013;151(2):573–81.PubMedCrossRef
89.
Samson AC, et al. Brain activation predicts treatment improvement in patients with major depressive disorder. J Psychiatr Res. 2011;45(9):1214–22.PubMed
90.
Roy M, et al. Medial prefrontal cortex activity during memory encoding of pictures and its relation to symptomatic improvement after citalopram treatment in patients with major depression. J Psychiatry Neurosci JPN. 2010;35(3):152–62.PubMed
91.
Walsh ND, et al. A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy. Biol Psychiatry. 2007;62(11):1236–43.PubMedCrossRef
92.
Pizzagalli DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2011;36(1):183–206.CrossRef
93.
Salvadore G, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry. 2009;65(4):289–95.PubMedCrossRef
94.
Salvadore G, et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2010;35(7):1415–22.CrossRef
95.
Brockmann H, et al. The value of HMPAO SPECT in predicting treatment response to citalopram in patients with major depression. Psychiatry Res. 2009;173(2):107–12.PubMedCrossRef
96.
Vakili K, et al. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biol Psychiatry. 2000;47(12):1087–90.PubMedCrossRef
97.
Frodl T, et al. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry. 2004;65(4):492–9.PubMedCrossRef
98.
Frodl T, et al. Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study. J Clin Psychiatry. 2011;72(4):448–57.PubMedCrossRef
99.
MacQueen GM, et al. Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol Psychiatry. 2008;64(10):880–3.PubMedCrossRef
100.
Wagner G, et al. Differential effects of serotonergic and noradrenergic antidepressants on brain activity during a cognitive control task and neurofunctional prediction of treatment outcome in patients with depression. J Psychiatry Neurosci JPN. 2010;35(4):247–57.PubMedCrossRef
101.
Konarski JZ, et al. Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. J Psychiatry Neurosci JPN. 2009;34(3):175–80.PubMed
102.
Milak MS, et al. Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment. Psychiatry Res. 2009;173(1):63–70.PubMedPubMedCentralCrossRef
103.
Won E-S, et al. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder. Neuropsychobiology. 2012;66(4):221–9.PubMedCrossRef
104.
Myung W, et al. Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology (Berlin). 2013;225(2):283–90.CrossRef
105.
Umene-Nakano W, et al. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol Oxf Engl. 2010;24(12):1764–71.CrossRef
106.
Kang R-H, et al. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1317–21.PubMedCrossRef
107.
Kim Y-G, et al. Serotonin-related polymorphisms in TPH1 and HTR5A genes are not associated with escitalopram treatment response in Korean patients with major depression. Neuropsychobiology. 2014;69(4):210–9.PubMedCrossRef
108.
Illi A, et al. Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? Eur Arch Psychiatry Clin Neurosci. 2011;261(2):95–102.PubMedCrossRef
109.
Bozina N, et al. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2008;9(3):190–7.CrossRef
110.
Arias B, et al. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol. 2003;23(6):563–7.PubMedCrossRef
111.
Sahraian S, et al. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness in iranian patients with major depressive disorder. Iran J Psychiatry. 2013;8(2):86–91.PubMedPubMedCentral
112.
Reimherr F, et al. Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. Psychiatry Res. 2010;175(1–2):67–73.PubMedCrossRef
113.
Baffa A, et al. Norepinephrine and serotonin transporter genes: impact on treatment response in depression. Neuropsychobiology. 2010;62(2):121–31.PubMedCrossRef
114.
Gressier F, et al. 5-HTTLPR modulates antidepressant efficacy in depressed women. Psychiatr Genet. 2009;19(4):195–200.PubMedCrossRef
115.
Huezo-Diaz P, et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry J Ment Sci. 2009;195(1):30–8.CrossRef
116.
Porcelli S, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2012;22(4):239–58.CrossRef
117.
Kraft JB, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry. 2007;61(6):734–42.PubMedCrossRef
118.
Hu X-Z, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007;64(7):783–92.PubMedCrossRef
119.
Lewis G, et al. Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. Br J Psychiatry J Ment Sci. 2011;198(6):464–71.CrossRef
120.
Chang HS, et al. Interaction of 5-HTT and HTR1A gene polymorphisms in treatment responses to mirtazapine in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34(4):446–54.PubMedCrossRef
121.
Lee S-H, et al. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine. Neuropsychobiology. 2010;62(3):198–206.PubMedCrossRef
122.
Min W, et al. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berlin). 2009;205(3):409–17.CrossRef
123.
Kim H, et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006;296(13):1609–18.PubMedCrossRef
124.
Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15(5):473–500.PubMedCrossRef
125.
Peters EJ, et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry. 2004;9(9):879–89.PubMedCrossRef
126.
Arias B, et al. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology. 2013;67(1):41–7.PubMedCrossRef
127.
Hong C-J, et al. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenom J. 2006;6(1):27–33.CrossRef
128.
Wang H-C, et al. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacology (Berlin). 2011;213(4):773–9.CrossRef
129.
Peters EJ, et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genom. 2009;19(1):1–10.CrossRef
130.
Serretti A, et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2004;129B(1):36–40.CrossRef
131.
Tsai S-J, et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(4):637–41.PubMedCrossRef
132.
Benedetti F, et al. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berlin). 2009;203(1):155–60.CrossRef
133.
Tsai S-J, et al. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord. 2009;113(1–2):183–7.PubMedCrossRef
134.
Baune BT, et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2008;33(4):924–32.CrossRef
135.
Arias B, et al. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord. 2006;90(2–3):251–6.PubMedCrossRef
136.
Szegedi A, et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenom J. 2005;5(1):49–53.CrossRef
137.
Tiwari AK, et al. Analysis of 34 candidate genes in bupropion and placebo remission. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP. 2013;16(4):771–81.
138.
Tzeng D-S, et al. MAOA gene polymorphisms and response to mirtazapine in major depression. Hum Psychopharmacol. 2009;24(4):293–300.PubMedCrossRef
139.
Domschke K, et al. Monoamine oxidase A variant influences antidepressant treatment response in female patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):224–8.PubMedCrossRef
140.
Tadić A, et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2007;144B(3):325–31.CrossRef
141.
Lucae S, et al. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2010;20(1):65–8.CrossRef
142.
Horstmann S, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2010;35(3):727–40.CrossRef
143.
McMahon FJ, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804–14.PubMedPubMedCentralCrossRef
144.
Kawaguchi DM, Glatt SJ. GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis. Pharmacogenomics. 2014;15(11):1451–9.PubMedPubMedCentralCrossRef
145.
Fabbri C, et al. Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2013;23(7):612–21.CrossRef
146.
Ventura-Juncá R, et al. Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study. BMC Psychiatry. 2014;14:220.PubMedPubMedCentralCrossRef
147.
Liu Z, et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett. 2007;414(2):155–8.PubMedCrossRef
148.
Licinio J, et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry. 2004;9(12):1075–82.PubMedCrossRef
149.
Binder EB, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36(12):1319–25.PubMedCrossRef
150.
Kirchheiner J, et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics. 2008;9(7):841–6.PubMedCrossRef
151.
Lekman M, et al. The FKBP5-gene in depression and treatment response–an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry. 2008;63(12):1103–10.PubMedPubMedCentralCrossRef
152.
Ellsworth KA, et al. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genom. 2013;23(3):156–66.CrossRef
153.
Uher R, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167(5):555–64.PubMedCrossRef
154.
Baune BT, et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry. 2010;67(6):543–9.PubMedCrossRef
155.
Baghai TC, et al. The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neurosci Lett. 2004;363(1):38–42.PubMedCrossRef
156.
Saab YB, et al. Renin-angiotensin-system gene polymorphisms and depression. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(5):1113–8.PubMedCrossRef
157.
Segman RH, et al. Angiotensin converting enzyme gene insertion/deletion polymorphism: case–control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia. Am J Med Genet. 2002;114(3):310–4.PubMedCrossRef
158.
Hong C-J, et al. Association study of angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders. J Neural Transm Vienna Austria 1996. 2002;109(9):1209–14.
159.
Wu Y, et al. The I/D polymorphism of angiotensin-converting enzyme gene in major depressive disorder and therapeutic outcome: a case-control study and meta-analysis. J Affect Disord. 2012;136(3):971–8.PubMedCrossRef
160.
Taylor WD, et al. BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenom J. 2011;11(2):146–54.CrossRef
161.
Choi M-J, et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res. 2006;1118(1):176–82.PubMedCrossRef
162.
Kocabas NA, et al. Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol. 2011;26(1):1–10.PubMedCrossRef
163.
Chi MH, et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J Affect Disord. 2010;126(3):430–5.PubMedCrossRef
164.
Domschke K, et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP. 2010;13(1):93–101.
165.
Katsuki A, et al. Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). CNS Spectr. 2012;17(3):155–63.PubMedCrossRef
166.
Yoshimura R, et al. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1022–5.PubMedCrossRef
167.
Kang RH, et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol Oxf Engl. 2010;24(12):1755–63.CrossRef
168.
Zou Y-F, et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology. 2010;61(2):71–8.PubMedCrossRef
169.
Uher R, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenom J. 2009;9(4):225–33.CrossRef
170.
Lin E, et al. Association study of a brain-derived neurotrophic-factor polymorphism and short-term antidepressant response in major depressive disorders. Pharmacogenom Pers Med. 2008;1:1–6.
171.
Yoshida K, et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol Oxf Engl. 2007;21(6):650–6.CrossRef
172.
Hennings JM, et al. Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: findings from an extended tag SNP approach. PLoS One. 2013;8(6):e64947.PubMedPubMedCentralCrossRef
173.
Porcelli S, et al. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci JPN. 2011;36(2):87–113.PubMedCrossRef
174.
Perlis RH. Pharmacogenomic testing and personalized treatment of depression. Clin Chem. 2014;60(1):53–9.PubMedCrossRef
175.
Zhang X, et al. Neither cytochrome P450 family genes nor neuroendocrine factors could independently predict the SSRIs treatment in the Chinese Han population. Pharmacopsychiatry. 2014;47(2):60–6.PubMedCrossRef
176.
177.
Uhr M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57(2):203–9.PubMedCrossRef
178.
Dong C, et al. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry. 2009;14(12):1105–18.PubMedPubMedCentralCrossRef
179.
Huang X, et al. ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. Pharmacogenomics. 2013;14(14):1723–30.PubMedCrossRef
180.
Breitenstein B, et al. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: results from a randomized clinical study. J Psychiatr Res. 2016;73:86–95.PubMedCrossRef
181.
182.
Ising M, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66(9):966–75.PubMedPubMedCentralCrossRef
183.
Ji Y, et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenom J. 2013;13(5):456–63.CrossRef
184.
GENDEP Investigators, MARS Investigators, STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170(2):207–17.CrossRef
185.
Poland RE, et al. Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression. Life Sci. 2013;92(20–21):967–70.PubMedPubMedCentralCrossRef
186.
Yoshimura R, et al. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol. 2009;24(6):489–94.PubMedCrossRef
187.
Dogan O, et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test. 2008;12(2):225–31.PubMedCrossRef
188.
Murphy GM, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163–9.PubMedCrossRef
189.
Yoshida K, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161(9):1575–80.PubMedCrossRef
190.
Houston JP, et al. Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder. Psychiatry Res. 2011;189(3):475–7.PubMedCrossRef
191.
Perlis RH, et al. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry. 2009;65(9):785–91.PubMedCrossRef
192.
Yu YW-Y, et al. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2005;30(9):1719–23.CrossRef
193.
Perlis RH, et al. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry. 2010;67(11):1110–3.PubMedCrossRef
194.
Sarginson JE, et al. FKBP5 polymorphisms and antidepressant response in geriatric depression. Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2010;153B(2):554–60.CrossRef
195.
Tsai S-J, et al. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2007;144B(8):1097–8.CrossRef
196.
Papiol S, et al. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007;104(1–3):83–90.PubMedCrossRef
197.
Gau Y-TA, et al. Evidence for association between genetic variants of p75 neurotrophin receptor (p75NTR) gene and antidepressant treatment response in Chinese major depressive disorder. Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2008;147B(5):594–9.CrossRef
198.
Staeker J, et al. Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. Genet Test Mol Biomark. 2014;18(1):20–31.CrossRef
199.
Xu Z, et al. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J Psychopharmacol Oxf Engl. 2012;26(3):349–59.CrossRef
200.
Serretti A, et al. No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. Psychiatry Investig. 2013;10(2):180–9.PubMedPubMedCentralCrossRef
201.
Iga J, et al. Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett. 2005;389(1):12–6.PubMedCrossRef
202.
Belzeaux R, et al. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J Psychiatr Res. 2010;44(16):1205–13.PubMedCrossRef
203.
Bocchio-Chiavetto L, et al. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2013;23(7):602–11.CrossRef
204.
Belzeaux R, et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry. 2012;2:e185.PubMedPubMedCentralCrossRef
205.
206.
Mamdani F, et al. Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2014;15(2):135–44.CrossRef
207.
Guilloux J-P, et al. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2015;40(3):701–10.CrossRef
208.
Hennings JM, et al. RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. Transl Psychiatry. 2015;5:e538.PubMedPubMedCentralCrossRef
209.
210.
Cattaneo A, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38(3):377–85.CrossRef
211.
Domschke K, et al. Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP. 2014;17(8):1167–76.
212.
Binder EB, et al. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology. 2009;34(1):99–109.PubMedCrossRef
213.
Rojas PS, et al. Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: a pilot study. Psychiatry Res. 2011;189(2):239–45.PubMedCrossRef
214.
Haile CN, et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP. 2014;17(2):331–6.
215.
García-Sevilla JA, et al. Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2010;20(10):721–30.CrossRef
216.
Harley J, et al. Orosomucoid influences the response to antidepressants in major depressive disorder. J Psychopharmacol Oxf Engl. 2010;24(4):531–5.CrossRef
217.
Wolkowitz OM, et al. Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Mol Psychiatry. 2012;17(2):164–72.PubMedCrossRef
218.
Moaddel R, et al. D-serine plasma concentration is a potential biomarker of (R, S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berlin). 2015;232(2):399–409.CrossRef
219.
220.
Lopez JP, et al. Regulatory role of miRNAs in polyamine gene expression in the prefrontal cortex of depressed suicide completers. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP. 2014;17(1):23–32.
221.
Ising M, et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression—a potential biomarker? Biol Psychiatry. 2007;62(1):47–54.PubMedCrossRef
222.
Svenningsson P, et al. Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram. Mol Psychiatry. 2014;19(9):962–4.PubMedPubMedCentralCrossRef
223.
Viikki M, et al. TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. Neurosci Lett. 2010;468(1):80–4.PubMedCrossRef
224.
Yoshida K, et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol. 2008;23(2):121–8.PubMedCrossRef
225.
Paddock S, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007;164(8):1181–8.PubMedCrossRef
226.
Breitenstein B, et al. Are there meaningful biomarkers of treatment response for depression? Drug Discov Today. 2014;19(5):539–61.PubMedCrossRef
227.
228.
Olbrich S, Arns M. EEG biomarkers in major depressive disorder: discriminative power and prediction of treatment response. Int Rev Psychiatry Abingdon Engl. 2013;25(5):604–18.CrossRef
229.
Labermaier C, et al. Biomarkers predicting antidepressant treatment response: how can we advance the field? Dis Mark. 2013;35(1):23–31.CrossRef
Metadata
Title
Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years
Authors
G. Voegeli
M. L. Cléry-Melin
N. Ramoz
P. Gorwood
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Drugs / Issue 18/2017
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-017-0819-9

Other articles of this Issue 18/2017

Drugs 18/2017 Go to the issue

Adis Drug Evaluation

Nonacog Beta Pegol: A Review in Haemophilia B

Adis Drug Evaluation

Aripiprazole Lauroxil: A Review in Schizophrenia

AdisInsight Report

Abemaciclib: First Global Approval

Adis Drug Evaluation

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events

Adis Drug Evaluation

Tofacitinib: A Review in Rheumatoid Arthritis

Adis Drug Evaluation

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma